ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "radiography and treatment"

  • Abstract Number: 716 • 2016 ACR/ARHP Annual Meeting

    Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors

    Susanne Juhl Pedersen1, Ulrich Weber2, Roula Said Nahal3, Inge Juul Sorensen1, Anne Gitte Loft4, Niels Tvede1, Gina Kollerup1, Lars Juul1, Gorm Thamsborg1, Ole Rintek Madsen1, Jakob M. Møller5, Lone Balding6, Anne Grethe Jurik7 and Mikkel Østergaard8, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 2Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, 3Ambroise Paré Hospital, Boulogne-Billancourt, France, 4Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, 5Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, 6Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, 7Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark

    Background/Purpose: Only few studies have investigated long-term radiographic progression in the spine of patients with ankylosing spondylitis (AS). Moreover, no studies have reported changes in…
  • Abstract Number: 3210 • 2016 ACR/ARHP Annual Meeting

    10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes

    Merete Lund Hetland1, Kristian Stengaard-Pedersen2, Peter Junker1, Hanne Lindegaard1, Torkell Ellingsen1, Jan Pødenphant2, Henrik Skjødt1, Aage Vestergaard2, Bo Jannik Ejbjerg1, Søren Jacobsen1, Niels Steen Krogh1, Mikkel Ostergaard1 and Kim Hørslev-Petersen2, 1Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Glostrup, Denmark, 2Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark

    Background/Purpose:  Few RCTs have investigated long-term (10+ years) outcomes of goal-directed synovitis suppression in early rheumatoid arthritis (RA). The CIMESTRA trial was a 2-year double-blinded…
  • Abstract Number: 954 • 2014 ACR/ARHP Annual Meeting

    Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

    Désirée van der Heijde1, Robert B. M. Landewé2, Philip J. Mease3, Iain B. McInnes4, Philip G. Conaghan5, Luminita Pricop6, Gregory Ligozio7, Hanno Richards8 and Shephard Mpofu9, 1Leiden University Medical Center, Leiden, Netherlands, 2Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 3Rheumatology Research, Swedish Medical Center, Seattle, WA, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 5NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, 9Novartis Pharma AG, Basel, Switzerland

    Background/Purpose Approximately two-thirds of patients (pts) with psoriatic arthritis (PsA) experience progressive joint damage associated with varying degrees of disability. Here we present the 1-year…
  • Abstract Number: 1361 • 2013 ACR/ARHP Annual Meeting

    Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort

    Mami Tamai1,2, Yoshikazu Nakashima3, Junko Kita4, Ayuko Takatani4, Ayako Nishino3, Takahisa Suzuki3, Yoshiro Horai3, Akitomo Okada5, Shin-ya Kawashiri3,6, Naoki Iwamoto3, Kunihiro Ichinose3, Kazuhiko Arima6, Hideki Nakamura3, Tomoki Origuchi7, Masataka Uetani8, Katsumi Eguchi9 and Atsushi Kawakami3, 1Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, 2Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 6Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 7Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 9Sasebo City General Hospital, Sasebo, Nagasaki, Japan

    Background/Purpose: Prognosis of the patients with rheumatoid arthritis (RA) nowadays is supposed to become better by treat-to-target (T2T) strategy. Osteitis determined by magnetic resonance imaging…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology